Blood brain barrier permeating platinum-peptide bioconjugates for the detection and destruction of brain tumours

Abstract

Brain tumours have poor prognosis and high rates of relapse. One of the main difficulties in diagnosing and treating brain cancers is the presence of the blood brain barrier (BBB). The BBB is a dynamic interface that separates the brain from the circulatory system, and hinders the entry of chemicals into the brain. Recently, targeting peptides have been shown to penetrate the BBB, and enter brain cancer cells through specific receptors. This project proposes to use targeting peptides to deliver theranostic platinum(II) complexes to brain tumours. This approach is envisaged to improve both brain cancer detection and treatment.





References:
[1]

K. Suntharalingam, J. J. Wilson, W. Lin, S. J. Lippard, “A Dual-targeting, p53-Independent, Apoptosis Inducing Platinum(II) Anticancer Complex, [Pt(BDIQQ)]Cl,” Metallomics, 6, 3, 437, 2013

[2]

K. Suntharalingam, A. L?czkowska, M. A. Furrer, Y. Wu, M. K. Kuimova, B. Therrien, A. J. White, R. Vilar, “A Cyclometallated Platinum Complex as a Selective Optical Switch for Quadruplex DNA,” Chemistry - A European Journal, 18, 51, 16277, 2012

[3]

T. C. Johnstone, K. Suntharalingam, S. J. Lippard, “Third row transition metals for the treatment of cancer,” Phil. Trans. R Soc. A., 373, 2037, 185, 2015

[4]

R. Sousa-Nunes, L. L. Yee, A. P. Gould, “Fat cells reactivate quiescent neuroblasts via TOR and glial insulin relays in Drosophila,” Nature, 471, 7339, 508, 2011

[5]

A. M. Thayer, “Improving peptides,” Chemical & Engineering News Archive, 89, 22, 13, 2011


Biological Areas:

Chemical Biology
Biotechnology

BBSRC Area:

Animal disease, health and welfare